Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
09/2003
09/04/2003CA2473602A1 Oral pediatric trimethobenzamide formulations and methods
09/04/2003CA2473340A1 Formulations comprising a glp-1 compound and a delivery agent, and uses thereof
09/04/2003CA2467836A1 Interfacial biomaterials
09/04/2003CA2467833A1 Pharmaceutical compositions in particulate form
09/03/2003EP1340769A1 CD4-gamma2 and CD4-IgG2 chimeras
09/03/2003EP1340503A1 Solution aerosol formulation containing esters of 3, 17-dihydroxy oestratriene derivates for pulmonary delivery
09/03/2003EP1340496A1 Pharmaceutical preparation of percutaneous absorption type
09/03/2003EP1340495A1 Extended release formulations of erythromycin derivatives
09/03/2003EP1340493A1 Solid support for extemporaneous homeopathic medicine
09/03/2003EP1340492A1 Aerosol formulations for pulmonary administration of medicaments having systemic effects
09/03/2003EP1339792A2 Surfactant-containing cosmetic, dermatological and pharmaceutical agents
09/03/2003EP1339789A2 Cosmetic, pharmaceutical and dermatological products containing an electrolyte
09/03/2003EP1339766A1 Surfactant-free cosmetic, dermatological and pharmaceutical agents
09/03/2003EP1339753A2 Percarboxylated polysaccharides, and a process for their preparation
09/03/2003EP1339749A1 Dextran-hemoglobin conjugates as blood substitutes
09/03/2003EP1339714A1 Novel sulfonamide-substituted pyrazolopyridine derivatives
09/03/2003EP1339440A1 An implantable or insertable therapeutic agent delivery device
09/03/2003EP1339438A2 Methods for preventing transplant rejection in the eye
09/03/2003EP1339432A1 Molecular inclusion compounds consisting of biocatalytically obtained, linear, water-insoluble polysaccharides and of fatty acids or their derivatives
09/03/2003EP1339431A1 Improved oral delivery of peptides using enzyme-cleavable membrane translocators
09/03/2003EP1339430A1 Freeze-dried pantoprazole preparation and pantoprazole injection
09/03/2003EP1339429A2 Composition containing statins and calcium for improved cardiovascular health
09/03/2003EP1339425A2 Vaccine composition containing transforming growth factor alpha
09/03/2003EP1339418A1 Improved ophthalmic and contact lens solutions containing simple saccharides as preservative enhancers
09/03/2003EP1339414A2 L-histidine in ophthalmic solutions
09/03/2003EP1339413A1 Complexes of phosphate derivatives
09/03/2003EP1339412A1 Formulation containing phosphate derivatives of electron transfer agents
09/03/2003EP1339408A1 Drug formulation having improved oral tolerability
09/03/2003EP1339403A2 Repinotan kit
09/03/2003EP1339396A2 Magnetic particles for the targeted regional therapy
09/03/2003EP1339395A2 Edible pga (propylene glycol alginate) coating composition
09/03/2003EP1339394A1 Method and preparation for binding acetaldehyde in saliva, stomach and large intestine
09/03/2003EP1339393A2 A method for restoring a fat-pad
09/03/2003EP1339392A2 Solid polyunsaturated fatty acid compositions
09/03/2003EP1339390A2 Laboratory scale milling process
09/03/2003EP1339389A1 Compositions for sustained delivery of hydrophobic drugs and process for the preparation thereof
09/03/2003EP1339388A1 Particulate inhalation carrier
09/03/2003EP1339387A2 Stable, aerosolizable suspensions of proteins (e.g. insulin, dnase) in ethanol
09/03/2003EP1339386A2 Reversible gelling system for ocular drug delivery
09/03/2003EP1339385A1 Skin cream stimulating the surface bloodstream
09/03/2003EP1339294A1 Nutritional composition for an immune condition
09/03/2003EP1233794B1 A bioabsorbable drug delivery system
09/03/2003EP1214300B1 Rate-controlled particles
09/03/2003EP1128821B1 A capsule based drug delivery system
09/03/2003EP1032381B1 Naringin and naringenin as preventive or treating agent for hepatic diseases
09/03/2003EP1019021B1 Stabilized preparations for use in metered dose inhalers
09/03/2003EP0969812B1 Ophthalmic compositions including glycerin and propylene glycol
09/03/2003EP0964675B1 Dry powder inhaler excipient, process for its preparation and pharmaceutical compositions containing it
09/03/2003EP0877562B1 Water dispersible compositions containing natural hydrophilic, water-insoluble pigments, methods of preparing same and their use
09/03/2003EP0833612B1 New pharmaceutical composition with anaesthetic effect
09/03/2003EP0804159B1 Sphingosomes for enhanced drug delivery
09/03/2003EP0797435B1 Controlled release matrix for pharmaceuticals
09/03/2003EP0758198B1 Non-separable starch-oil compositions
09/03/2003EP0651646B1 Therapeutic conjugates of toxins and drugs
09/03/2003CN1440423A Immunoadhesin for the prevention of rhinovirus infection
09/03/2003CN1440298A Medical aerosol formulation
09/03/2003CN1440294A Medical components comprising human parathyroid hormone and medicinal compositions for nasal administration containing the components
09/03/2003CN1440291A Pharmaceutical composition based on non-steroid anti-inflammatory agent
09/03/2003CN1440282A Improved thyroid hormone formulations
09/03/2003CN1440278A Pharmaceutical compositions of 2'-deoxy-2'-(fluoromethy lene) cytidine
09/03/2003CN1440277A Particular carrier with active components with improved oral absorbing performance
09/03/2003CN1440276A Use of oligosaccharides to stimulate beta-endorphin production
09/03/2003CN1439429A Composite nutritive complementary tablets (particles)
09/03/2003CN1439366A Stable heptyl platinum solution preparation
09/03/2003CN1439360A Dry powder composition for improvement of effective position medical deposit
09/03/2003CN1120019C Insulin preparations containing NaCl
09/03/2003CN1119997C Percutaneous tap preparation containing fentanyl
09/02/2003US6613879 FAP-activated anti-tumour compounds
09/02/2003US6613807 Linking low molecular weight drugs containing a carboxylic acid group and an amine, thiol, alcohol or phenol, which is released when hydrolysis occurs
09/02/2003US6613790 Prodrugs of COX-2 inhibitors
09/02/2003US6613788 Transdermal patch to systemically deliver effective dose of histamine comprising histamine and controlled release preparation which releases drug over period of time sufficient to obtain stable elevated levels in circulating blood
09/02/2003US6613751 Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation
09/02/2003US6613536 Complementarity-determining region; monoclonal antibodies; antiidiotypic antibodies; autoantibodies; heavy chains; light chains; polypeptides; amino acid sequences; DNA; carriers; use for treatment of systemic lupus erythematosus in humans
09/02/2003US6613362 Comprising mixture of Western and Chinese herbs which can act as an intestinal bowel soother
09/02/2003US6613360 Spray-coated pharmaceutical powder compositions for transdermal administration using a needleless syringe comprise seed particles coated with a pharmaceutical composition, the said coated seed particles having an average size of about 10
09/02/2003US6613355 Semi-solid delivery vehicle and pharmaceutical compositions
09/02/2003US6613351 Vector including a complex between at least one compound having an amidine polar head of formula where m is 14 and at least one of nucleic acids molecules, polypeptides, glycosylated polypeptides and membrane
09/02/2003US6613344 Methods utilizing stinging cells/capsules
09/02/2003US6613336 H.influenzae type b polysaccharide-substantially pure, refolded meningococcal outer membrane protein conjugate; vaccines
09/02/2003US6613332 Oral administration of therapeutic proteins
09/02/2003US6613330 Methods and compositions for preventing anti-Gal production in xenograft recipients
09/02/2003US6613308 Administering to the respiratory tract a drug at a dose which is at least about two-fold less than the dose required by oral administration.
09/02/2003CA2081709C Controlled release pharmaceutical compositions
08/2003
08/28/2003WO2003070983A1 RNA INTERFERENCE MEDIATED INHIBITION OF PROTEIN KINASE C ALPHA (PKC-ALPHA) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
08/28/2003WO2003070970A2 RNA INTERFERENCE MEDIATED INHIBITION OF NF-KAPPA B/REL-A GENE EXPRESSION USING SHORT INTERFEREING NUCLEIC ACID (siNA)
08/28/2003WO2003070968A2 RNA INTERFERENCE MEDIATED INHIBITION OF GASTRIC INHIBITORY POLYPEPTIDE (GIP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
08/28/2003WO2003070966A2 RNA INTERFERENCE MEDIATED TARGET DISCOVERY AND TARGET VALIDATION USING SHORT INTERFERING NUCLEIC ACID (siNA)
08/28/2003WO2003070918A2 Rna interference by modified short interfering nucleic acid
08/28/2003WO2003070914A2 RNA INTERFERENCE MEDIATED INHIBITION OF FOS GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
08/28/2003WO2003070912A2 RNA INTERFERENCE MEDIATED INHIBITION OF EPIDERMAL GROWTH FACTOR RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
08/28/2003WO2003070911A2 Rna interference mediated inhibition of type 1 insulin-like growth factor receptor (igf-1r)
08/28/2003WO2003070910A2 INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND VEGF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
08/28/2003WO2003070909A2 Microparticles with adsorbed polypeptide-containing molecules
08/28/2003WO2003070905A2 Electroporation methods for introducing bioactive agents into cells
08/28/2003WO2003070903A2 RNA INTERFERENCE MEDIATED INHIBITION OF GRB2-ASSOCIATED BINDING PROTEIN 2 (GAB2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
08/28/2003WO2003070895A2 RNA INTERFERENCE MEDIATED TREATMENT OF ALZHEIMER'S DISEASE USING SHORT INTERFERING NUCLEIC ACID (siNA)
08/28/2003WO2003070888A2 Rna interference mediated inhibition of checkpoint kinase-1 (chk-1) gene expression using short interfering nucleic acid
08/28/2003WO2003070887A2 RNA INTERFERENCE MEDIATED INHIBITION OF POLYCOMB GROUP PROTEIN EZH2 GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
08/28/2003WO2003070886A2 Inhibition of protein tyrosine phosphatase type iva expression byshort interfering nucleic acid
08/28/2003WO2003070885A2 SHORT INTERFERING NUCLEIC ACID INHIBITION OF STEAROYL-CoA DESATURASE (SCD) GENE
1 ... 1107 1108 1109 1110 1111 1112 1113 1114 1115 1116 1117 1118 1119 1120 1121 1122 1123 1124 1125 1126 1127 ... 1712